In the BioHarmony Drug Report Database
Cu, Paragard T 380a, Tatum-t, Cuprymina (copper) is a small molecule pharmaceutical. Copper was first approved as Cu on 1982-01-01. It has been approved in Europe to treat radionuclide imaging. It is known to target glycine receptor subunit alpha-2, glycine receptor subunit alpha-3, transient receptor potential cation channel subfamily A member 1, glycine receptor subunit alpha-1, and zinc-activated ligand-gated ion channel.
Image (chem structure or protein)